Biography
Dr. Kyla Agtarap grew up in the Ottawa region and completed her Bachelor of Science in Biomedical Sciences at the University of Ottawa. She went on to complete her PharmD at the University of Waterloo. She was the only Canadian bilingual pharmacy resident for the 2023-2024 cycle, working with both The Ottawa Hospital and Hôpital Montfort. Post-residency, she decided to pursue her career as a clinical pharmacist at the Ottawa Hospital, as well as her growing role in the University of Ottawa's School of Pharmaceutical Sciences.
Kyla also hopes to continue her research in psychotherapy with the rapidly changing landscape of psychedelics in Canada.
Expertise
- Pharmacotherapy
- Pharmaceutical practice
- Psychedelics
Research Projects
Kyla has participated in research since her undergraduate degree in the varying fields of data mining, substance use, pharmacokinetics, oncology, antimicrobial stewardship, epidemiology, and animal and human physiology.
She has worked on two peer-reviewed and published research papers: Adverse Events Associated with Immune Checkpoint Inhibitors: An Overview of Systematic Reviews, and Drug-drug Interactions with CFTR Modulator Therapy in Cystic Fibrosis: Focus on Trikafta®/Kaftrio®. She has also had the honour of presenting her self-led research on psychedelics, Psilocybin for the treatment of obsessive-compulsive disorder symptoms: Exploring user-generated online content, at the Interdisciplinary Conference in Psychology (2023) and the Canadian Society of Pharmacology and Therapeutics Conference (2024).
Her most recent research was for her residency titled: “Evaluating the quality and safety of a protocol managing the drug interaction of cyclosporine and nirmatrelvir/ritonavir inkidney transplant patients at The Ottawa Hospital”. This research was presented at three conferences during her residency year: Conference on Retroviruses and Opportunistic Infections 2024, Association of Medical Microbiology and Infectious Disease Canada 2024, and the Canadian Pharmacy Education and Research Conference 2024.
Publications
- Purkayastha D, Agtarap K, Wong K, et al. Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on trikafta®/kaftrio®. Journal of Cystic Fibrosis. 2023;22(3):478-483. doi:10.1016/j.jcf.2023.01.005
- Kanji S, Morin S, Agtarap K, et al. Adverse events associated with immune checkpoint inhibitors: Overview of Systematic Reviews. Drugs. 2022;82(7):793-809. doi:10.1007/s40265-022-01707-1
- Agtarap K, Giguerre P, Deschênes MJ. Evaluation of a Protocol for Managing Cyclosporine and Nirmatrelvir/Ritonavir Drug-Drug Interaction. In: Conference on Retroviruses and Opportunistic Infections. ; 2024. https://www.croiconference.org/wp-content/uploads/sites/2/resources/2024/croi2024-abstract-ebook-v3.pdf